Shopping Cart
- Remove All
Your shopping cart is currently empty
YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $176 | In Stock | |
| 5 mg | $373 | In Stock | |
| 10 mg | $590 | In Stock | |
| 25 mg | $876 | In Stock | |
| 50 mg | $1,180 | In Stock | |
| 100 mg | $1,590 | In Stock | |
| 200 mg | $2,130 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $428 | In Stock |
| Description | YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM). |
| Targets&IC50 | Ole1:39 nM, SCD:30.4 μM |
| In vitro | YTX-465 rescued growth to a similar magnitude but was >100-fold more potent than YTX-528(EC50 = 0.013 μM). Kinetic growth studies demonstrated that the most effective concentration of YTX-465 (0.050 μM) restored growth rates to that of approximately 40% of the wild-type strain treated with the same concentration of YTX-465[1]. In wild-type yeast, YTX-465 strongly reduced fatty desaturation in a concentration-dependent manner, with a 50% reduction in desaturation at 0.03 μM YTX-465[1]. |
| Molecular Weight | 458.51 |
| Formula | C25H26N6O3 |
| Cas No. | 2225824-53-1 |
| Smiles | Cc1nn(C)c2cc(ccc12)-c1noc(n1)C1CCN(CC1)C(=O)CNC(=O)c1ccccc1 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (109.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.36 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.